SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma - Quaterly Results

27 May 2023 Evaluate
A fair growth of 22.87% in the revenue at Rs. 35474.40 millions was reported in the March 2023 quarter as compared to Rs. 28871.70 millions during year-ago period.The Net proft of the company remain more or less same to Rs. 6448.00  millions from Rs. 8021.60 millions ,decline by -19.62%.The company reported a good operating profit of 9800.00 millions compared to 9203.40 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 35474.40 28871.70 22.87 127922.80 112871.40 13.33 127922.80 112871.40 13.33
Other Income 2881.70 4133.70 -30.29 4337.60 6709.90 -35.36 4337.60 6709.90 -35.36
PBIDT 9800.00 9203.40 6.48 21646.80 21443.90 0.95 21646.80 21443.90 0.95
Interest 489.70 49.10 897.35 1149.80 169.40 578.75 1149.80 169.40 578.75
PBDT 9310.30 8407.20 10.74 20497.00 20527.40 -0.15 20497.00 20527.40 -0.15
Depreciation 1150.00 1012.20 13.61 4353.50 4152.60 4.84 4353.50 4152.60 4.84
PBT 8160.30 7395.00 10.35 16143.50 16374.80 -1.41 16143.50 16374.80 -1.41
TAX 1712.30 -626.60 -373.27 3839.40 1827.70 110.07 3839.40 1827.70 110.07
Deferred Tax -26.10 -880.70 -97.04 -230.80 -1969.30 -88.28 -230.80 -1969.30 -88.28
PAT 6448.00 8021.60 -19.62 12304.10 14547.10 -15.42 12304.10 14547.10 -15.42
Equity 585.90 585.90 0.00 585.90 585.90 0.00 585.90 585.90 0.00
PBIDTM(%) 27.63 31.88 -13.34 16.92 19.00 -10.93 16.92 19.00 -10.93

Aurobindo Pharma Share Price

1385.65 -0.45 (-0.03%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×